Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
1920
Trial Sponsor
Clinical Trial Start Date
June 21, 2021
0Primary Completion Date
January 19, 2023
0Study Completion Date
January 19, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Drug0
Device0
Intervention Name
Placebo0
CELLECTRA™ 20000
INO-47000
Interventional Trial Phase
Phase 20
Official Name
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers0
Last Updated
January 30, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
